<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860090</url>
  </required_header>
  <id_info>
    <org_study_id>A-276</org_study_id>
    <nct_id>NCT03860090</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety in Pacemaker and Defibrillator Implantation Via Cephalic Versus Axillary Vein Access (CEPHAX)</brief_title>
  <acronym>CEPHAX</acronym>
  <official_title>Prospective Randomized Comparison of Efficacy and Safety in Pacemaker and Defibrillator Implantation Via Cephalic Versus Axillary Vein Access. The CEPHAX Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Castilla-La Mancha Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Castilla-La Mancha Health Service</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates the efficacy and safety of axillary versus cephalic venous
      access in the pacemakers and defibrillators implantation.

      Half of participants will receive the implant via fluoroscopy guided axillary venous access
      and the other half will receive the implant via improved cephalic venous access.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">February 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Success</measure>
    <time_frame>30 days</time_frame>
    <description>Success of the implant through the assigned access vein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implant Complications</measure>
    <time_frame>30 days</time_frame>
    <description>All implant related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lead Complications</measure>
    <time_frame>From date of implant until the date of first documented, assessed up to 48 months</time_frame>
    <description>Lead fracture or dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper limb thrombosis</measure>
    <time_frame>From date of implant until the date of first documented, assessed up to 48 months</time_frame>
    <description>Thrombosis of the ipsilateral upper limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>30 days</time_frame>
    <description>Implant related pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Implant related bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to access.</measure>
    <time_frame>From cutaneous incision to reach the right atrium with the guidewire, assessed up to 45 minutes.</time_frame>
    <description>Time until reaching venous access.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time of implant.</measure>
    <time_frame>From the skin incision to the skin suture, assessed up to 180 minutes.</time_frame>
    <description>Intervention time.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pacemakers</condition>
  <condition>Defibrillators</condition>
  <condition>Complication</condition>
  <condition>Pacemaker Electrode Lead Fracture</condition>
  <arm_group>
    <arm_group_label>AXILLARY VEIN ACCESS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEPHALIC VEIN ACCESS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker implant</intervention_name>
    <description>Implantation of endovenous cardiac stimulation device.</description>
    <arm_group_label>AXILLARY VEIN ACCESS</arm_group_label>
    <arm_group_label>CEPHALIC VEIN ACCESS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillator implant</intervention_name>
    <description>Implantation of endovenous cardiac defibrillation device.</description>
    <arm_group_label>AXILLARY VEIN ACCESS</arm_group_label>
    <arm_group_label>CEPHALIC VEIN ACCESS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AXILLARY VEIN ACCESS</intervention_name>
    <description>Fluoroscopy-guided axillary puncture to get vein access</description>
    <arm_group_label>AXILLARY VEIN ACCESS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CEPHALIC VEIN ACCESS</intervention_name>
    <description>Optimized cephalic vein cutdown to get vein access</description>
    <arm_group_label>CEPHALIC VEIN ACCESS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a endovenous pacemaker or defibrillator indication.

        Exclusion Criteria:

          -  Pre-existing ipsilateral pacing electrode.

          -  Previous ipsilateral lymphadenectomy.

          -  Indication of cardiac resynchronization therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Jiménez Díaz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arrhythmia Unit Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Calkins H, Ramza BM, Brinker J, Atiga W, Donahue K, Nsah E, Taylor E, Halperin H, Lawrence JH, Tomaselli G, Berger RD. Prospective randomized comparison of the safety and effectiveness of placement of endocardial pacemaker and defibrillator leads using the extrathoracic subclavian vein guided by contrast venography versus the cephalic approach. Pacing Clin Electrophysiol. 2001 Apr;24(4 Pt 1):456-64.</citation>
    <PMID>11341082</PMID>
  </reference>
  <reference>
    <citation>Squara F, Tomi J, Scarlatti D, Theodore G, Moceri P, Ferrari E. Self-taught axillary vein access without venography for pacemaker implantation: prospective randomized comparison with the cephalic vein access. Europace. 2017 Dec 1;19(12):2001-2006. doi: 10.1093/europace/euw363.</citation>
    <PMID>28064251</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cephalic Vein</keyword>
  <keyword>Axillary Vein</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03860090/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

